Sanofi (SNY) Receives ‘Analyst’ Rating

Sanofi (SNY) : The consensus on Sanofi (SNY) based on 4 analyst recommendation on the company stock is 2, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 2 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.

Sanofi (SNY) : The highest level Sanofi (SNY) is projected to reach is $56 for the short term and the lowest estimate is at $46. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $51 and the possibility the share price can swing is $7.07.


Sanofi (NYSE:SNY): The stock opened in the green at $38.74 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $39.0411 and a low of $38.6 for the day. The stock did not find buyers even at the lows and closed at $38.92 recording a loss of -0.76%. 3,159,045 shares exchanged hands during the trading day. The stock had closed at $39.22 in the previous days trading.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.